Taiwan FDA registration f04f8a1ae4e9e7e5d9cd0cdd67f9ca74
"Haifong Biomedical" Edoxaban correction solution group
TW: “海奉生物醫學” Edoxaban 校正液組
Taiwan·Risk Class 2·HYPHEN BioMed·Registered Jun 15, 2021 – Jun 15, 2026ExpiredRegistration details
- Analysis ID
- f04f8a1ae4e9e7e5d9cd0cdd67f9ca74
- Customs Code
- DHA05603466402
Company information
- Manufacturer
- HYPHEN BioMed
- Manufacturer Country
- France
- Authorized Representative
- SYSMEX TAIWAN CO., LTD.
Product details
- Intended Use
- This product is lyophilized human plasma doped with different concentrations of Edoxaban for correction of Edoxaban measurement.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1150 Calibrated Products
- Import Information
- QMS/QSD;; 輸入
Dates and status
- Registration Date
- Jun 15, 2021
- Expiry Date
- Jun 15, 2026
About this record
Access comprehensive regulatory information for "Haifong Biomedical" Edoxaban correction solution group in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number f04f8a1ae4e9e7e5d9cd0cdd67f9ca74 and manufactured by HYPHEN BioMed. The authorized representative in Taiwan is SYSMEX TAIWAN CO., LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices